Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
1. In patients with pouchitis associated with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC), the use of oral...
Gastroenterology
Reports of high-impact gastroenterology studies by medical professionals
Structured exercise intervention improves survival in colon cancer patients
1. In this randomized controlled trial, patients with resected stage III or high-risk stage II colon cancer who completed adjuvant...
Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease
1. In patients with Crohn’s disease (CD), fecal calprotectin (FC) was a useful biomarker for monitoring small bowel lesions and...
Time-restricted eating does not confer changes in sleep, mood, or quality of life
1. Time-restricted eating, regardless of timing of the eating window, did not result in significant changes in sleep, mood, or...
Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
1. In this series of target trial emulations, several common medications were not found to significantly affect the risk of...
Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
1. Use of Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors among adults with cirrhosis receiving diuretic therapy was associated with lower incidence...
Food compounds associated with disease activity in inflammatory bowel disease
1. This retrospective cohort study identified several dietary compounds, specifically fatty acids, that are associated with remission in inflammatory bowel...
Volumetric diet and time-restricted eating demonstrate similar outcomes for weight reduction
1. In this randomized controlled trial comparing the volumetrics diet (VD) and time-restricted eating (TRE), both interventions led to significant...
Fecal microbiota transplantation may be more effective than vancomycin in treating primary C. difficile infection
1. In this randomized controlled trial, a higher proportion of patients who underwent fecal microbiota transplantation achieved clinical cure of...
Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events...